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Antioestrogenic tamoxifen is widely used for the treatment of
breast cancer (Early Breast Cancer Trialists Collaborative Group,
1998) and even for the prevention of breast cancer in high-risk
patients (Fisher et al, 1998). Toremifene is another antioestrogen,
which has been proven to be effective in the treatment of breast
cancer (Hayes et al, 1995; Wiseman and Goa, 1997). Because
breast cancer is the most common cancer of women (Garfinkel 
et al, 1994), antioestrogens have become one of the commonest
types of drugs used by women. 
Antioestrogens act by blocking oestrogen receptors not only in
breast cancer cells but also in reproductive organs possessing these
receptors. Therefore, use of antioestrogens can cause a number of
gynaecological consequences (Cohen et al, 1994; Barakat, 1996).
It is known, mostly from cross-sectional studies, that antioestrogen
use is associated with vasomotor symptoms and vaginal dryness
and irritation (Buckley and Goa, 1989; Wiseman and Goa, 1997),
which may be signs and consequences of hypooestrogenism. In the
uterus, and especially in the endometrium, the effect of antioestro-
gens resembles that of oestrogens (Lahti et al, 1993; Friedl and
Jordan, 1994), and in this regard tamoxifen may be more potent
than toremifene at least in animal experiments (DiSalle et al,
1990). The use of both tamoxifen and toremifene has been linked
to the risk of endometrial polyps (Tomás et al, 1995; Barakat,
1996) and tamoxifen may increase the risk of endometrial cancer
(Fisher et al, 1994; Rutqvist et al, 1995; Fisher et al, 1998; Early
Breast Cancer Trialists Collaborative Group, 1998). However,
these data have been collected mostly from cross-sectional studies,
which are prone to several methodological weaknesses. Therefore
we designed a prospective comparative trial to assess gynaecolo-
gical consequences of the use of tamoxifen and toremifene in
patients with breast cancer. 
PATIENTS AND METHODS 
With the permission of the local ethics committee, we studied 167
postmenopausal (more than 6 months since their last menstrual
period, FSH > 40 IU/l) patients with stage II–III breast cancer
(Table 1). The patients had undergone surgery for breast cancer 6–8
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Summary To assess and compare the gynaecological consequences of the use of 2 antioestrogens we examined 167 postmenopausal
breast cancer patients before and during the use of either tamoxifen (20 mg/day, n = 84) or toremifene (40 mg/day, n = 83) as an adjuvant
treatment of stage II–III breast cancer. Detailed interview concerning menopausal symptoms, pelvic examination including transvaginal
sonography (TVS) and collection of endometrial sample were performed at baseline and at 6, 12, 24 and 36 months of treatment. In a
subgroup of 30 women (15 using tamoxifen and 15 toremifene) pulsatility index (PI) in an uterine artery was measured before and at 6 and 12
months of treatment. The mean (±SD) follow-up time was 2.3 ± 0.8 years. 35% of the patients complained of vasomotor symptoms before the
start of the trial. This rate increased to 60.0% during the first year of the trial, being similar among patients using tamoxifen (57.1%) and
toremifene (62.7%). Vaginal dryness, which was present in 6.0% at baseline, increased during the use of tamoxifen (26.2%) and toremifene
(24.1%). Endometrial thickness increased from baseline (3.9 ± 2.7 mm) to 6.8 ± 4.2 mm at 6 months (P < 0.001), and no difference emerged
between the 2 regimens in this regard. Before the start of the antioestrogen regimen, the endometrium was atrophic in 71 (75.5%) and
proliferative in 19 of 94 (20.2%) samples; 4 patients had benign endometrial polyps. During the use of antioestrogen altogether 339
endometrial samples were taken (159 in tamoxifen group, 180 in toremifene group). The endometrium was proliferative more often in the
tamoxifen group (47.8%) than in the toremifene group (32.2%) (P < 0.0001). 20 patients had a total of 24 polyps (17 in tamoxifen and 9 in
toremifene group, P < 0.05) during the use of antioestrogens. One patient in the toremifene group developed endometrial adenocarcinoma at
12 months, and one patient had breast cancer metastasis on the endometrium. Tamoxifen failed to affect the PI in the uterine artery, but
toremifene reduced it by 15.0% (P < 0.05) by 12 months. In conclusion, tamoxifen and toremifene cause similarly vasomotor and vaginal
symptoms. Neither regimen led to the development of premalignant endometrial changes. Our data suggest that so close endometrial
surveillance as used in our study may not be mandatory during the first 3 years of use of antioestrogen treatment. © 2001 Cancer Research
Campaign http://www.bjcancer.com
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Breast Cancer Group Adjuvant Toremifene versus Tamoxifen
Trial (FBCG II) (Holli, 1998). The cancer had spread to the axil-
lary nodes in all patients, but no other metastases were detected in
a thorough clinical examination. The patients received local radio-
therapy 5 times a week for 5 weeks, and were randomized to start
a 3-year course either with tamoxifen (20 mg/day, Tadex®, Orion,
Turku, Finland), or with toremifene (40 mg/day, Fareston®, Orion,
Turku, Finland), which are expected to have similar efficacy in the
prevention of cancer recurrence (Hayes et al, 1995; Wiseman and
Goa, 1997; Pyrhönen et al, 1999). The study groups did not differ
from each other with regard to relevant clinical data, such as age,
history of hysterectomy, or the use of oestrogen replacement
therapy before the diagnosis of breast cancer (Table 1). The
patients were otherwise healthy, but 53 patients (29 in tamoxifen
group, 24 in toremifene group) used different antihypertensive
drugs (beta-blockers, diuretics, calcium channel blockers) to
control elevated blood pressure, and 27 women smoked (8 in
tamoxifen and 19 in toremifene group). 
Before the start of antioestrogen, all patients underwent a
careful clinical examination (weight, height, blood pressure), and
pelvic examination was also carried out. Pap smears were
collected, and transvaginal sonographic (TVS) examination
(Aloka SSD 500) was performed in all patients with a uterus
and/or ovaries to assess pelvic anatomy, including endometrial
thickness. If endometrial thickness (double layer) exceeded 8 mm
or if an endometrial polyp was suspected, 10–20 ml of sterile
saline were injected into the uterine cavity and TVS was repeated
(Widrich et al, 1996). Any polyp was removed through
hysteroscopy and examined under microscope. Endometrial
biopsies were collected (Pipelle endometrial aspirator, Unimar,
Wilmington, CN) (Chambers and Chambers, 1992) and examined
under microscope by the same experienced pathologist (TW). The
histology of the endometrium was classified as atrophic (small
simple, tubular glands lined by cuboidal epithelium, the nuclei are
centrally placed, no mitoses seen) or mildly proliferative (small
tubular glands lined by cuboidal to columnar epithelium, the
nuclei are ovoid and basally or centrally located, some mitoses are
seen). The patients were seen at 6 months, 12 months, 24 months
and 36 months, and at each visit the examinations done at recruit-
ment were repeated. In addition, at recruitment and at each follow-
up visit the patients were carefully interviewed for gynaecological
symptoms, possible adverse effects, and for the occurrence of
uterine bleeding. Patients experiencing uterine bleeding at any
time during the follow-up were instructed to report at the research
centre immediately, and TVS and endometrial biopsy were
repeated. 
To study the effect of antioestrogens on pulsatility index (PI) of
the uterine artery, we selected a subgroup of 30 patients (15 using
tamoxifen, 15 using toremifene), who were studied with Doppler
equipment (Hitachi 515A, Tokyo, Japan, 6.5 MHz endovaginal
transducer) before the start of medication and at 6 and 12 months
of trial, as described before (Cacciatore et al, 1998). These assess-
ments were always done by the same investigator (BC), who was
blinded to the code of the treatment. 
The numerical variables of the groups were compared with
Student’s two-tailed unpaired t-test. The changes in variables
within the groups were first subjected to the analysis of variance
and if this showed a difference, the significance of the difference
was tested by paired t-test. The comparison of two proportions in
case of paired samples (e.g. endometrial samples) was performed
by McNemar’s test. Pearson Chi-square statistics were applied
when comparing the distribution of categorical variables of 2 inde-
pendent samples. The data are presented as mean ± SD. A P value
of <0.05 was considered significant. 
RESULTS 
A total of 167 patients have been followed for a mean of 2.3 ± 0.8
years. All patients completed one year follow-up, 130 patients (61
tamoxifen users, 69 toremifene users) 2 years follow-up, and 94
patients (42 tamoxifen users, 52 toremifene users) 3 years follow-
up. The trial is still going on in 36 patients. 17 patients (11 in
tamoxifen group, 6 in toremifene group) failed to report according
to the protocol, and 20 patients discontinued the use of antioestro-
gens, 5 because of adverse effects (3 in tamoxifen group, 2 in
toremifene group) and 15 because of recurrence of breast cancer 
(7 in tamoxifen group, 8 in toremifene group). Thus 37 patients
have discontinued the follow-up. 
Vasomotor symptoms, which were complained by 59 patients
(35.3%) (32 in tamoxifen, 27 in toremifene group) before the trial,
increased in frequency but were equally common and severe in
both groups (Table 2). Vaginal symptoms (dryness, irritation,
discharge) increased during the use of antiestrogen in both groups
(Table 2). 
Small uterine fibroids (<4 cm) were detected in 13 patients
starting tamoxifen and in 15 patients starting toremifene. Neither
tamoxifen nor toremifene affected the size of the fibroids or
caused new fibroids. Simple ovarian cysts (<3 cm) were detected
in 4 women starting toremifene, but they disappeared during
the first 6 months on toremifene. Thecoma on the left ovary
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Table 1 Clinical characteristics of the study population (n = 167) using
either tamoxifen (20 mg/day, n = 84), or toremifene (40 mg/day, n = 83)
(mean ± SD), (range) or (percent) 
Tamoxifen Toremifene All 
(n = 84) (n = 83) (n = 167) 
Age (y) 63.2 ± 7.8 62.4 ± 8.9 62.8 ± 8.4 
(48–77) (44–81) (44–81) 
Age at 
Menarche 13.3 ± 1.6 13.7 ± 1.9 13.5 ± 1.8 
(9–18) (9–19) (9–19) 
Menopause 49.9 ± 3.5 48.8 ± 4.2 49.4 ± 3.9 
(40–58) (33–56) (33–58) 
Nulliparous 29 (34.5%) 16 (19.3%) 45 (26.9%) 
Body mass index (kg/m2) 27.4 ± 0.5 27.0 ± 0.5 27.2 ± 0.3 
(19–40) (19–38) (19–40) 
Hysterectomized 21 (25.0%) 17 (20.5%) 38 (22.7%) 
Previous use of HRT 37 (44.0%) 36 (42.9%) 73 (43.7%) 
Use of antihypertensive drugs 29 (34.5%) 24 (28.9%) 53 (31.7%) 
Smoking 8 (9.5%) 19 (22.9%) 27 (16.2%) 
Breast cancer classification 
Tumour size 
T1 49 (58.3%) 38 (45.8%) 87 (52.1%) 
T2 30 (35.7%) 39 (47.0%) 69 (41.3%) 
T3 5 (6.0%) 6 (7.2%) 11 (5.6%) 
Nodal status 
N1 83 (98.8%) 80 (96.4%) 163 (97.6%) 
N2 1 (1.2%) 3 (3.6%) 4 (2.4%) 
Surgery 
Radical 55 (65.5%) 56 (67.5%) 111 (66.5%) 
Conservative 29 (34.5%) 27 (32.5%) 56 (33.5%) (50 ´ 45 ´ 62 mm) was diagnosed in one patient after one year’s
use on tamoxifen; it was removed laparoscopically. Before the
start of antioestrogen, 5 women (3 in tamoxifen group, 2 in
toremifene group) complained of symptoms of a partial prolapse
of the uterus. The antioestrogen regimen failed to affect these
symptoms, and vaginal hysterectomy was performed in these
patients during the trial; the symptoms were relieved. Pap smears
revealed no pre-malignant lesions before or during the trial in any
patient. 
The mean endometrial thickness, which was 3.9 ± 2.7 mm
before the start of antioestrogen, increased to 6.8 ± 4.2 mm (P <
0.001) already during the first 6 months but no further thickening
was seen later (Table 3). There were no differences between the
tamoxifen and toremifene groups in this regard. Age or time since
the onset of menopause did not correlate with the increase in
endometrial thickness (data not shown). In total, vaginal bleedings
occurred in 13 women (10.1%) during the trial (5 in tamoxifen
group, 8 in toremifene group) between 6 months and 2.9 years of
use of antioestrogens. Of these patients, endometrial polyps were
detected in 4 and endometrium showed mild proliferation in 8 and
atrophy in one patient. 
Tamoxifen failed to affect PI in the uterine artery at 6 or 12
months, but toremifene reduced it from 2.24 ± 0.65 at baseline to
1.85 ± 0.69 at 12 months (P < 0.05). The changes in PI or endo-
metrial thickness did not correlate with each other in the whole
series or in either subgroup. 
Before the initiation of antioestrogens, adequate endometrial
samples were obtained from 94 of 129 patients (73%) with intact
uterus (44 in tamoxifen group, 50 in toremifene group), whereas
endometrial sampling did not succeed in 35 patients due to cervical
stenosis (n = 25) or intolerable pain (n = 10) (Table 3). At baseline
the endometrium was atrophic in 71 patients (75.5%) and prolifer-
ative in 19 patients (20.2%) and contained polyps in 4 women (Table
3). Of the 19 patients with proliferative endometrium, 16 had
used oestrogen replacement therapy until the diagnosis of breast
cancer. Tamoxifen increased the mean incidence of proliferative
endometrium more (from 20.4% to 46.8%) than toremifene (from
20.0% to 32.2%) did (P < 0.0001) (Table 3). Endometrial histology
was not relative to endometrial thickness in the whole series or in
either of the subgroups (Figure 1). The diagnosis of endometrial
polyp was made 24 times (17 in tamoxifen group, 7 in toremifene
group, P < 0.05), in 20 patients, during the study period (Table 3).
All these polyps were removed hysteroscopically. Polyps did not
recur in patients whose polyps were removed at entry. 3 patients
using tamoxifen and one patient using toremifene developed polyps
repeatedly at 1 or 2 years intervals during the trial. 
One patient using toremifene proved to have endometrial adeno-
carcinoma at 12 months. She had no bleeding but the endometrium
was thick (12 mm) and contained a polyp. The polyp, which was
removed through hysteroscopy, showed hyperplasia, and hysterec-
tomy with bilateral oophorectomy was performed. Well-differenti-
ated adenocarcinoma limited to the endometrium was detected in a
histological examination. In addition, both ovaries contained small
metastases of breast cancer. In another woman using tamoxifen
and reporting no bleeding, endometrial thickness was 7 mm at 12
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Table 2 Vasomotor and vaginal symptoms before and during first year’s
tamoxifen (20 mg day–1, n = 84) or toremifene (40 mg day–1, n = 83) use in
postmenopausal patients with breast cancer 
Tamoxifen Toremifene 
Vasomotor symptoms
Before 32 (38.1%) 27 (32.5%) 
Mild 12 (14.3%) 16 (19.8%) 
Moderate 10 (11.9%) 11 (13.3%) 
Severe 1 (1.2%) 0 
During trial 48 (57.1%) 52 (62.7%) 
Mild 18 (21.4%) 13 (15.7%) 
Moderate 16 (19.0%) 27 (32.5%) 
Severe 14 (21.4%) 12 (14.5%) 
Vaginal irritation or dryness
Before 
Dryness 5 (5.9%) 5 (6.0%) 
During trial 
Dryness 8 (9.5%) 5 (6.0%) 
Irritation 8 (9.5%) 4 (4.8%) 
Discharge 6 (7.1%) 11 (13.2%)
Table 3 Endometrial findings in postmenopausal breast cancer patients starting the use of either tamoxifen (20 mg/day, n = 63) or toremifene 
(40 mg/day, n = 66) 
Before At 6 months P value* 12 months P value* 24 months P value* 36 months P value* 
Tamoxifen 
biopsy succeeded 44/63 (69.8%) 48/63(76.2%) 50/63 (79.4%) 35/45 (77.8%) 26/29 (89.7%) 
atrophy 34 (77.3%) 18 (37.5%) <0.001 23 (46.0%) <0.005 14 (40.0%) <0.005 10 (38.5%) <0.05 
mild proliferation 9 (20.4%) 25 (52.1%) <0.001 23 (46.0%) <0.05 16 (45.7%) <0.05 12 (46.1%) NS 
polyp 1 (2.3%) 5 (10.6%) NS 4 (8.0%) NS 4 (11.4%) <0.05 4 (15.4%) <0.05 
carcinoma 0 0 0 1# (2.9%) 0 
endometrial thickness 
(mm), (mean ± SD) 3.5 ± 1.9 7.5 ± 4.8 <0.001 7.1 ± 3.5 <0.001 7.8 ± 4.5 <0.001 7.6 ± 3.9 <0.001 
Toremifene 
biopsy succeeded 50/66 (75.8%) 50/66 (75.8%) 55/66 (83.3%) 46/52 (88.5%) 29/35 (82.9%) 
atrophy 37 (74.0%) 37 (74.0%) NS 29 (52.7%) <0.05 28 (60.9%) NS 20 (69.0%) NS 
mild proliferation 10 (20.0%) 11 (22.0%) NS 25 (45.5%) <0.005 15 (32.6%) NS 7 (24.1%) NS 
polyp 3 (6.0%) 2 (4.0%) NS 0 NS 3 (6.5%) NS 2 (6.9%) NS 
carcinoma 0 0 1§ (1.8%) 0 0 
endometrial thickness 
(mm), (mean ± SD) 4.2 ± 3.2 6.2 ± 3.5 <0.001 7.1 ± 4.0 <0.001 7.3 ± 3.1 <0.001 7.7 ± 4.3 <0.001 
* Compared with initial; # breast cancer metastasis on endometrium; § endometrial adenocarcinoma gr 1. months, and a biopsy revealed metastasis of breast cancer. At
laparotomy, metastases of breast cancer were seen in all pelvic and
intra-abdominal organs. 
DISCUSSION 
The use of antioestrogens has drastically increased in modern clin-
ical practice (Garfinkel et al, 1994; Fisher et al, 1998). Therefore it
is important to assess all the possible consequences of the use of
antioestrogens, appearing also outside of the breasts, and our study
focused on gynaecological findings and symptoms. It is clear from
our study that both tamoxifen and toremifene caused and/or wor-
sened vasomotor symptoms, although these regimens did not differ
from each other in this regard. In previous cross-sectional studies,
the occurrence of severe hot flushes during antioestrogen regimens
has varied between 20 and 30% (Buckley and Goa, 1989; Love 
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Figure 1 Endometrial thickness compared to endometrial histology in 129 postmenopausal patients using either tamoxifen (n = 63) or toremifene (n = 66) et al, 1991; Hayes et al, 1995). Compared with this rate the frequency
of hot flushes was higher in our study (60%), but 33–38% of all
study patients reported these symptoms already at baseline exami-
nation. Vaginal dryness and irritation were also common prior to
the trial but they increased during both regimens; this is in agree-
ment with a previous cross-sectional study (Hayes et al, 1995).
Thus our data imply that tamoxifen and toremifene probably cause
a hypo-oestrogenic milieu at least in the vagina, because vaginal
dryness was a common complaint. Such a hypo-oestrogenic effect
was not seen in the endometrium. It is difficult to deduce why the
vagina and endometrium behave so differently in regard to anti-
oestrogens, but it is probably related to different receptors status in
these organs. However, only 5 patients (3%) discontinued the use
of antioestrogens because of hypo-oestrogenic adverse effects. 
The use of tamoxifen and toremifene led to a similar thickening
of the endometrium already at 6 months follow-up and this effect
was maintained during the whole trial. This finding is in accor-
dance with one previous prospective study (Tomás et al, 1995).
The mechanism of endometrial thickening is not fully understood,
but it could be a reflection of the oestrogenic effect of anti-
oestrogens. This is supported by the appearance of a proliferative
endometrium, although no relation between endometrial histology
and endometrial thickness was seen. With regard to endometrial
effect, tamoxifen and toremifene appear fairly similar, although
the incidence of proliferative endometrium was higher in tamox-
ifen users. Furthermore, the appearance of endometrial polyps may
be a reflection of oestrogenic effect. However, what is noteworthy
in our data is that endometrial thickening in antioestrogen users is
not a sign of endometrial proliferation but in effect, a thick
endometrium can be atrophic. This has been detected also in some
previous studies (Cohen et al, 1993; Touraine et al, 1995; Ismail,
1996). Thus, endometrial thickening is probably a result of the
enlargement of subendometrial glands (Goldstein, 1994; Neven,
1995; McGonigle et al, 1998) and is no indication for endometrial
biopsy. 
Toremifene reduced significantly the PI in the uterine artery by
12 months whereas tamoxifen, contrary to the results of a previous
study (Kedar et al, 1994), had no effect on PI. We did not have a
control group, but in view of previous data (Hillard et al, 1992;
Pirhonen et al, 1993) it is unlikely that one year’s increase in age
would have reduced the PI; in contrast, it would rather have
increased it. Pulsatility index reflects a resistance to blood flow
distal to the site of measurement and, thus, its reduction is a sign of
decreased vascular resistance. Consequently, toremifene may have
caused a true vasodilatation in the uterine artery and, in this regard,
the effect of toremifene resembles that of oestrogens (Cacciatore 
et al, 1998). The lacking effect of tamoxifen on Pl may suggest a
weaker oestrogenic effect on uterine vasculature but, of course, the
rather small number of patients limits any firm conclusions. It was
also of interest that the changes in endometrial thickness and in PI
were in no relation to each other. This may suggest that antioestro-
gens operate through different mechanisms of action on the
endometrium and on vascular wall. 
Endometrial safety during long-term use of antioestrogens has
caused much concern among gynaecologists. This issue is import-
ant, since a history of breast cancer, alone, denotes a 1.6-fold risk
of endometrial cancer (Adami et al, 1997). The risk of endometrial
carcinoma in tamoxifen users has been shown to be increased in
some (Fisher et al, 1994; Rutqvist et al, 1995; Fisher et al, 1998)
although not all studies (Ribeiro and Swindell, 1988; Stewart et al,
1996), and close endometrial surveillance has been recommended
to these patients (Fornander et al, 1993; van Leeuwen et al, 1994;
Tesoro et al, 1999). We followed prospectively a rather large
number of postmenopausal patients, whose endometrial status was
carefully examined before and during the trial. Both regimens,
used for a mean of 2.3 years, were associated with endometrial
thickening and with an increased incidence of proliferative
endometrium. However, only one patient showed a hyperplastic
polyp and primary endometrial carcinoma. Thus the risk of
endometrial carcinoma in the whole study population (0.03/100
woman-years) is even smaller than in a Finnish normal population
in this age group (0.06/100 woman-years; Finnish Cancer
Register, 1995). Thus our data do not lend any support to the fear
that antioestrogens increase the risk of endometrial carcinoma at
least in the first 2–3 years of use. Our data seriously question the
rationale of endometrial surveillance of antioestrogen users
(Fornander et al, 1993; Tesoro et al, 1994; van Leeuwen et al,
1994). 
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